EP Patent

EP3636635A1 — Imaging agents

Assigned to Scintomics GmbH · Expires 2020-04-15 · 6y expired

What this patent protects

This invention relates to compounds of formula I or la: Y 1 is -EuK, -EuFA, -EuPG, -L 1 -EuK, -L 1 -EuFA, -L 1 -EuPG or -L 3 -EuE; Y 2 is -L 4 -EuK, - L 4 -EuFA, - L 4 -EuPG, -EuE, or -L 2 -EuE; Z is a chelating moiety; and the other substituents are as defin…

USPTO Abstract

This invention relates to compounds of formula I or la: Y 1 is -EuK, -EuFA, -EuPG, -L 1 -EuK, -L 1 -EuFA, -L 1 -EuPG or -L 3 -EuE; Y 2 is -L 4 -EuK, - L 4 -EuFA, - L 4 -EuPG, -EuE, or -L 2 -EuE; Z is a chelating moiety; and the other substituents are as defined herein. Also provided are formulations comprising such a compound, as well as methods of imaging or methods for the treatment of cancer comprising use of such a compound or formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP3636635A1
Jurisdiction
EP
Classification
—
Expires
2020-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Scintomics GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.